1. Home
  2. BCDA vs EDBL Comparison

BCDA vs EDBL Comparison

Compare BCDA & EDBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • EDBL
  • Stock Information
  • Founded
  • BCDA N/A
  • EDBL 2020
  • Country
  • BCDA United States
  • EDBL United States
  • Employees
  • BCDA N/A
  • EDBL N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • EDBL Farming/Seeds/Milling
  • Sector
  • BCDA Health Care
  • EDBL Consumer Staples
  • Exchange
  • BCDA Nasdaq
  • EDBL Nasdaq
  • Market Cap
  • BCDA 9.4M
  • EDBL 2.6M
  • IPO Year
  • BCDA N/A
  • EDBL 2022
  • Fundamental
  • Price
  • BCDA $2.62
  • EDBL $2.60
  • Analyst Decision
  • BCDA Strong Buy
  • EDBL
  • Analyst Count
  • BCDA 1
  • EDBL 0
  • Target Price
  • BCDA $25.00
  • EDBL N/A
  • AVG Volume (30 Days)
  • BCDA 47.2K
  • EDBL 221.6K
  • Earning Date
  • BCDA 03-26-2025
  • EDBL 03-31-2025
  • Dividend Yield
  • BCDA N/A
  • EDBL N/A
  • EPS Growth
  • BCDA N/A
  • EDBL N/A
  • EPS
  • BCDA N/A
  • EDBL N/A
  • Revenue
  • BCDA $71,000.00
  • EDBL $14,069,000.00
  • Revenue This Year
  • BCDA N/A
  • EDBL $2.43
  • Revenue Next Year
  • BCDA N/A
  • EDBL $42.42
  • P/E Ratio
  • BCDA N/A
  • EDBL N/A
  • Revenue Growth
  • BCDA N/A
  • EDBL 7.88
  • 52 Week Low
  • BCDA $1.63
  • EDBL $1.82
  • 52 Week High
  • BCDA $6.45
  • EDBL $311.75
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 57.96
  • EDBL 38.50
  • Support Level
  • BCDA $2.45
  • EDBL $1.82
  • Resistance Level
  • BCDA $2.69
  • EDBL $5.43
  • Average True Range (ATR)
  • BCDA 0.20
  • EDBL 0.45
  • MACD
  • BCDA 0.02
  • EDBL -0.04
  • Stochastic Oscillator
  • BCDA 87.34
  • EDBL 27.84

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About EDBL Edible Garden AG Incorporated

Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses, together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.

Share on Social Networks: